Resolvin E1 (TP-317) treatment for pancreatic cancer
Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer
This project is developing a new drug called TP-317, based on a natural molecule (Resolvin E1), to reduce tumor growth and tumor-related inflammation in people with pancreatic cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thetis Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Deep River, United States) |
| Project ID | NIH-11351574 on NIH RePORTER |
What this research studies
Researchers are developing TP-317, a drug based on Resolvin E1 that helps clear dead cell debris and calm harmful inflammation in tumors. Early animal studies show TP-317 can slow tumor growth, boost anti-tumor immune responses, and add benefit when given with chemotherapy. This R44 grant funds key preclinical safety, dosing, and efficacy studies in animals needed to support an IND application. If those studies succeed, TP-317 could move into human clinical trials for people with pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates would be people with pancreatic cancer—particularly those with advanced or chemo-resistant disease—though this grant supports preclinical work and any patient participation would occur later in clinical trials.
Not a fit: People without pancreatic cancer, or those seeking an immediately available treatment, will not benefit from this preclinical program until human trials are completed and the drug is approved.
Why it matters
Potential benefit: If successful, TP-317 could slow tumor growth, improve the immune response against pancreatic tumors, and make chemotherapy more effective, potentially improving survival and reducing side effects.
How similar studies have performed: Related laboratory and animal studies show Resolvin E1 can reduce inflammation and suppress tumors and may boost chemotherapy effects, but human benefit has not yet been proven.
Where this research is happening
Deep River, United States
- Thetis Pharmaceuticals, LLC — Deep River, United States (Active)
Researchers
- Principal investigator: Parkinson, John — Thetis Pharmaceuticals, LLC
- Study coordinator: Parkinson, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.